AVITA Medical (RCEL) Stock Forecast, Price Target & Predictions
RCEL Stock Forecast
AVITA Medical stock forecast is as follows: an average price target of $9.00 (represents a -23.53% downside from RCEL’s last price of $11.77) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
RCEL Price Target
The average price target for AVITA Medical (RCEL) is $9.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $9.00 to $9.00. This represents a potential -23.53% downside from RCEL's last price of $11.77.
RCEL Analyst Ratings
According to 5 Wall Street analysts, AVITA Medical's rating consensus is 'Buy'. The analyst rating breakdown for RCEL stock is 0 'Strong Buy' (0.00%), 4 'Buy' (80.00%), 1 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
AVITA Medical Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 14, 2024 | Matt O'Brien | Piper Sandler | $9.00 | $8.35 | 7.78% | -23.53% |
The latest AVITA Medical stock forecast, released on May 14, 2024 by Matt O'Brien from Piper Sandler, set a price target of $9.00, which represents a 7.78% increase from the stock price at the time of the forecast ($8.35), and a -23.53% decrease from RCEL last price ($11.77).
AVITA Medical Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $9.00 |
| Last Closing Price | $11.77 | $11.77 | $11.77 |
| Upside/Downside | -100.00% | -100.00% | -23.53% |
In the current month, the average price target of AVITA Medical stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to AVITA Medical's last price of $11.77. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 09, 2024 | Cowen & Co. | Buy | Buy | Hold |
| May 14, 2024 | Bank of America Securities | Buy | Buy | Hold |
| May 14, 2024 | Piper Sandler | Neutral | Downgrade | |
| Jun 27, 2023 | Cantor Fitzgerald | Overweight | Initialise | |
| Jun 16, 2021 | BTIG | Buy | Buy | Hold |
AVITA Medical's last stock rating was published by Cowen & Co. on Aug 09, 2024. The company gave RCEL a "Buy" rating, the same as its previous rate.
AVITA Medical Financial Forecast
AVITA Medical Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $13.64M | $11.75M | $10.55M | $9.46M | $9.09M | $8.34M | $7.54M | $6.94M | $7.02M | $10.30M | $8.77M | $5.10M | $5.06M | $3.88M |
| Avg Forecast | $17.26M | $17.54M | $17.82M | $18.10M | $33.07M | $29.43M | $25.67M | $22.03M | $23.20M | $19.44M | $14.52M | $11.08M | $14.20M | $13.40M | $11.30M | $10.28M | $8.80M | $7.48M | $7.32M | $7.24M | $8.28M | $7.33M | $4.94M | $5.10M | $3.88M | $7.97M | $3.61M |
| High Forecast | $18.22M | $18.51M | $18.81M | $19.11M | $34.91M | $31.07M | $27.10M | $23.26M | $24.49M | $20.52M | $15.33M | $11.70M | $15.89M | $14.15M | $11.93M | $10.85M | $9.29M | $7.48M | $7.32M | $7.24M | $8.28M | $7.33M | $4.94M | $5.10M | $3.88M | $7.97M | $3.61M |
| Low Forecast | $16.26M | $16.52M | $16.79M | $17.06M | $31.16M | $27.74M | $24.19M | $20.76M | $21.86M | $18.32M | $13.68M | $10.44M | $13.36M | $12.63M | $10.65M | $9.69M | $8.29M | $7.48M | $7.32M | $7.24M | $8.28M | $7.33M | $4.94M | $5.10M | $3.88M | $7.97M | $3.61M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 1 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.02% | 1.04% | 1.03% | 1.07% | 1.21% | 1.14% | 1.04% | 0.84% | 0.96% | 2.09% | 1.72% | 1.32% | 0.64% | 1.07% |
AVITA Medical's average Quarter revenue forecast for Dec 23 based on 5 analysts is $14.20M, with a low forecast of $13.36M, and a high forecast of $15.89M. RCEL's average Quarter revenue forecast represents a 4.03% increase compared to the company's last Quarter revenue of $13.64M (Sep 23).
AVITA Medical EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 1 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-8.53M | $8.31M | $-9.05M | $-5.19M | $-5.44M | $-6.12M | $-9.46M | $-8.45M | $-5.76M | $-4.53M | $-5.82M | $-5.46M | $-10.00M | $-12.90M |
| Avg Forecast | $-16.51M | $-16.77M | $-17.04M | $-17.32M | $-31.63M | $-28.15M | $-24.55M | $-21.08M | $-22.19M | $-18.59M | $-13.89M | $-11.82M | $-13.58M | $-12.82M | $-10.81M | $-12.22M | $-12.28M | $-7.16M | $-7.00M | $-11.69M | $-7.92M | $-7.01M | $-4.72M | $-8.66M | $-3.71M | $-7.62M | $-10.24M |
| High Forecast | $-15.56M | $-15.81M | $-16.06M | $-16.32M | $-29.81M | $-26.53M | $-23.14M | $-19.86M | $-20.91M | $-17.52M | $-13.09M | $-9.46M | $-12.78M | $-12.08M | $-10.19M | $-9.78M | $-9.82M | $-7.16M | $-7.00M | $-9.35M | $-7.92M | $-7.01M | $-4.72M | $-6.92M | $-3.71M | $-7.62M | $-8.19M |
| Low Forecast | $-17.43M | $-17.71M | $-17.99M | $-18.28M | $-33.39M | $-29.72M | $-25.92M | $-22.25M | $-23.43M | $-19.63M | $-14.66M | $-14.18M | $-15.20M | $-13.53M | $-11.41M | $-14.66M | $-14.73M | $-7.16M | $-7.00M | $-14.03M | $-7.92M | $-7.01M | $-4.72M | $-10.39M | $-3.71M | $-7.62M | $-12.29M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.67% | -0.77% | 0.74% | 0.42% | 0.76% | 0.87% | 0.81% | 1.07% | 0.82% | 0.96% | 0.67% | 1.47% | 1.31% | 1.26% |
4 analysts predict RCEL's average Quarter EBITDA for Sep 23 to be $-12.82M, with a high of $-12.08M and a low of $-13.53M. This is -254.22% lower than AVITA Medical's previous annual EBITDA (Jun 23) of $8.31M.
AVITA Medical Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 1 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-8.71M | $-10.38M | $-9.22M | $-5.35M | $-5.59M | $-6.26M | $-9.46M | $-8.48M | $-5.95M | $-4.72M | $-6.00M | $-5.64M | $-10.23M | $-12.91M |
| Avg Forecast | $-3.78M | $-3.78M | $-7.55M | $-7.55M | $-3.24M | $-6.07M | $-10.99M | $-15.98M | $-13.56M | $-15.94M | $-18.32M | $-12.03M | $-14.12M | $-17.27M | $-11.97M | $-12.44M | $-12.67M | $-13.00M | $-12.67M | $-11.90M | $-10.23M | $-12.28M | $-16.52M | $-8.92M | $-5.41M | $-4.74M | $-10.25M |
| High Forecast | $-3.49M | $-3.49M | $-6.99M | $-6.99M | $-3.00M | $-5.61M | $-10.17M | $-14.78M | $-9.04M | $-14.75M | $-16.94M | $-9.63M | $-13.06M | $-15.98M | $-11.08M | $-9.95M | $-10.14M | $-13.00M | $-12.67M | $-9.52M | $-10.23M | $-12.28M | $-16.52M | $-7.14M | $-5.41M | $-4.74M | $-8.20M |
| Low Forecast | $-4.05M | $-4.05M | $-8.10M | $-8.10M | $-3.47M | $-6.51M | $-11.79M | $-17.14M | $-18.08M | $-17.10M | $-19.64M | $-14.44M | $-15.14M | $-18.52M | $-12.84M | $-14.93M | $-15.21M | $-13.00M | $-12.67M | $-14.28M | $-10.23M | $-12.28M | $-16.52M | $-10.71M | $-5.41M | $-4.74M | $-12.30M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.50% | 0.87% | 0.74% | 0.42% | 0.43% | 0.49% | 0.80% | 0.83% | 0.48% | 0.29% | 0.67% | 1.04% | 2.16% | 1.26% |
AVITA Medical's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. RCEL's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
AVITA Medical SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 1 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $16.66M | $-3.84M | $14.84M | $11.66M | $10.41M | $10.80M | $12.36M | $10.60M | $8.87M | $9.42M | $9.07M | $7.00M | $11.74M | $14.67M |
| Avg Forecast | $127.28M | $129.32M | $131.39M | $133.50M | $243.85M | $217.06M | $189.28M | $162.49M | $171.09M | $143.36M | $107.05M | $81.71M | $104.68M | $98.82M | $83.33M | $75.81M | $64.90M | $55.19M | $53.96M | $53.39M | $61.02M | $54.02M | $36.41M | $37.61M | $28.61M | $58.76M | $26.63M |
| High Forecast | $134.36M | $136.52M | $138.71M | $140.94M | $257.43M | $229.15M | $199.82M | $171.54M | $180.62M | $151.35M | $113.02M | $86.26M | $117.19M | $104.32M | $87.97M | $80.03M | $68.51M | $55.19M | $53.96M | $53.39M | $61.02M | $54.02M | $36.41M | $37.61M | $28.61M | $58.76M | $26.63M |
| Low Forecast | $119.94M | $121.86M | $123.82M | $125.81M | $229.80M | $204.55M | $178.37M | $153.12M | $161.23M | $135.10M | $100.88M | $77.00M | $98.50M | $93.12M | $78.53M | $71.44M | $61.16M | $55.19M | $53.96M | $53.39M | $61.02M | $54.02M | $36.41M | $37.61M | $28.61M | $58.76M | $26.63M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.17% | -0.05% | 0.20% | 0.18% | 0.19% | 0.20% | 0.23% | 0.17% | 0.16% | 0.26% | 0.24% | 0.24% | 0.20% | 0.55% |
AVITA Medical's average Quarter SG&A projection for Dec 23 is $104.68M, based on 5 Wall Street analysts, with a range of $98.50M to $117.19M. The forecast indicates a 528.50% rise compared to RCEL last annual SG&A of $16.66M (Sep 23).
AVITA Medical EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 1 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.34 | $-0.41 | $-0.37 | $-0.24 | $-0.22 | $-0.25 | $-0.38 | $-0.34 | $-0.24 | $-0.19 | $-0.26 | $-0.26 | $-0.48 | $-0.61 |
| Avg Forecast | $-0.15 | $-0.15 | $-0.30 | $-0.30 | $-0.13 | $-0.24 | $-0.43 | $-0.63 | $-0.53 | $-0.63 | $-0.72 | $-0.53 | $-0.56 | $-0.68 | $-0.47 | $-0.40 | $-0.35 | $-0.51 | $-0.50 | $-0.46 | $-0.40 | $-0.48 | $-0.65 | $-0.35 | $-0.21 | $-0.19 | $-0.20 |
| High Forecast | $-0.14 | $-0.14 | $-0.28 | $-0.28 | $-0.12 | $-0.22 | $-0.40 | $-0.58 | $-0.36 | $-0.58 | $-0.67 | $-0.49 | $-0.51 | $-0.63 | $-0.44 | $-0.37 | $-0.33 | $-0.51 | $-0.50 | $-0.46 | $-0.40 | $-0.48 | $-0.65 | $-0.35 | $-0.21 | $-0.19 | $-0.20 |
| Low Forecast | $-0.16 | $-0.16 | $-0.32 | $-0.32 | $-0.14 | $-0.26 | $-0.46 | $-0.67 | $-0.71 | $-0.67 | $-0.77 | $-0.57 | $-0.60 | $-0.73 | $-0.51 | $-0.43 | $-0.38 | $-0.51 | $-0.50 | $-0.46 | $-0.40 | $-0.48 | $-0.65 | $-0.35 | $-0.21 | $-0.19 | $-0.20 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.50% | 0.87% | 0.92% | 0.68% | 0.43% | 0.50% | 0.82% | 0.84% | 0.50% | 0.29% | 0.74% | 1.22% | 2.57% | 3.07% |
According to undefined Wall Street analysts, AVITA Medical's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to RCEL previous annual EPS of $NaN (undefined).
AVITA Medical Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| APYX | Apyx Medical | $1.64 | $8.50 | 418.29% | Buy |
| TELA | TELA Bio | $2.76 | $8.00 | 189.86% | Buy |
| LUNG | Pulmonx | $6.13 | $13.00 | 112.07% | Buy |
| SGHT | Sight Sciences | $3.62 | $7.50 | 107.18% | Hold |
| RXST | RxSight | $38.04 | $70.14 | 84.38% | Buy |
| DCTH | Delcath Systems | $11.94 | $22.00 | 84.25% | Buy |
| TMDX | TransMedics Group | $65.71 | $116.33 | 77.04% | Buy |
| OFIX | Orthofix Medical | $17.93 | $24.00 | 33.85% | |
| SIBN | SI-BONE | $13.84 | $18.50 | 33.67% | Buy |
| NPCE | NeuroPace | $11.52 | $15.00 | 30.21% | Buy |
| IRMD | IRadimed | $53.00 | $60.00 | 13.21% | Buy |
| VREX | Varex Imaging | $15.16 | $17.00 | 12.14% | Buy |
| CVRX | CVRx | $13.16 | $14.25 | 8.28% | Buy |
| CLPT | ClearPoint Neuro | $16.34 | $15.00 | -8.20% | Buy |
| RCEL | AVITA Medical | $12.52 | $9.00 | -28.12% | Buy |